Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Webcast

Silence Therapeutics to Present at Jefferies Global Healthcare Conference


Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced the Company will present at the Jefferies Global Healthcare Conference on Thursday, June 6th at 2:30 p.m. ET.

The live webcast can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be available following the conference.

About Silence Therapeutics
Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence's proprietary mRNAi GOLDtm platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include zerlasiran designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and divesiran designed to address rare hematological diseases, including polycythemia vera. Silence also maintains ongoing research and development collaborations with AstraZeneca and Hansoh Pharma, among others. For more information, please visit https://www.silence-therapeutics.com/.


These press releases may also interest you

at 13:59
Paul Fleissner, M.D., a board-certified orthopaedic and pediatric orthopaedic surgeon at Crystal Clinic Orthopaedic Center, and chairman of the board, has performed the world's first meniscus repair using an innovative, new regenerative implant for...

at 13:48
The National Institute for Fitness and Sport (NIFS) is gearing up for the third running of Pump it for Parkinson's on Thursday April 10, 2025. NIFS along with their program partner, NuStep, are inviting senior living communities to take part in this...

at 13:36
Vitalacy, Inc., a leader in patient safety technology, is proud to announce the launch of its AI-driven Virtual Care solution, designed to enhance patient safety, reduce hospital falls, and optimize hospital efficiency through 24/7 AI-powered remote...

at 13:34
Talkiatry, a leading provider of high-quality, in-network psychiatric care, today announced that it has been named to the 2025 New York Digital Health 100 (DH100), a recognition that highlights the most exciting and innovative startups in New York....

at 13:30
Dr. Alexander Caudarella, Chief Executive Officer of the Canadian Centre on Substance Use and Addiction (CCSA), issued the following statement during his visit to Washington, D.C., this week. "Earlier this week, Prime Minister Justin Trudeau...

at 13:15
MediPrint® Ophthalmics, a clinical-stage ophthalmic drug delivery company, continues to advance its innovative glaucoma program following the successful completion of its Phase 2b clinical trial for LL-BMT1. As the company progresses towards the next...



News published on and distributed by: